Locally Advanced or Metastatic Urothelial Cancer – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Locally Advanced or Metastatic Urothelial Cancer Emerging Therapy and TPP Insights

Thelansis’s “Locally Advanced or Metastatic Urothelial Cancer Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Locally Advanced or Metastatic Urothelial Cancer Overview

Locally advanced or metastatic urothelial cancer is cancer of the bladder or urinary tract lining that has invaded nearby tissues or spread to distant sites. Blood in the urine is common, while pelvic pain or urinary obstruction may occur with advanced disease. Treatment depends on fitness, kidney function, prior therapy, and tumor features. Enfortumab vedotin plus pembrolizumab is a preferred first-line option for many eligible patients. When this combination is unsuitable, platinum-based chemotherapy may be used; patients whose disease does not progress after platinum therapy may receive avelumab maintenance. Molecular testing can identify alterations that guide later treatment: tumors with susceptible FGFR3 changes may respond to erdafitinib after prior therapy. Despite improved options, responses vary and resistance remains common. Research is testing new antibody-drug conjugates, targeted agents, and immunotherapy combinations to extend disease control while limiting toxicity.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)